Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lise Kjems

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Advances in Therapy|September 6, 2022
Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic CholestasisChad Gwaltney, Cristina Ivanescu, Lisa Karlsson, et al.
Advances in Therapy|September 6, 2022
Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver DiseasesChad Gwaltney, Stephanie Bean, Meredith Venerus, et al.
Diabetes Care|January 6, 2018
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) StudyRobert R Henry, Julio Rosenstock, Douglas S Denham, et al.
Hepatology (Baltimore, Md.)|April 8, 2026
OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trialAndrew S Allegretti, Giuseppe Cullaro, Paul Kwo, et al.
Diabetes Care|December 16, 2017
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 TrialJulio Rosenstock, John B Buse, Rehan Azeem, et al.
Journal of Clinical Pharmacology|October 4, 2008
Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteersPei Hu, Qi Yin, Fabienne Deckert, et al.
The Journal of Clinical Endocrinology and Metabolism|January 15, 2002
Pulsatile insulin secretion by human pancreatic isletsSoon H Song, Lise Kjems, Robert Ritzel, et al.
Diabetes|May 22, 2016
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor AntagonistMichael A Nauck, Joachim Kind, Lars D Köthe, et al.
Molecular Genetics and Metabolism Reports|September 6, 2023
Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trialReena Sharma, Caroline Hastings, Orna Staretz-Chacham, et al.
The Journal of Clinical Endocrinology and Metabolism|February 11, 2011
Skeletal muscle mitochondrial capacity and insulin resistance in type 2 diabetesSudip Bajpeyi, Magdalena Pasarica, Cedric Moro, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Advances in Therapy|September 6, 2022
Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic CholestasisChad Gwaltney, Cristina Ivanescu, Lisa Karlsson, et al.
Advances in Therapy|September 6, 2022
Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver DiseasesChad Gwaltney, Stephanie Bean, Meredith Venerus, et al.
Diabetes Care|January 6, 2018
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA<sub>1c</sub>: The FREEDOM-1 HBL (High Baseline) StudyRobert R Henry, Julio Rosenstock, Douglas S Denham, et al.
Hepatology (Baltimore, Md.)|April 8, 2026
OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trialAndrew S Allegretti, Giuseppe Cullaro, Paul Kwo, et al.
Diabetes Care|December 16, 2017
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 TrialJulio Rosenstock, John B Buse, Rehan Azeem, et al.
Journal of Clinical Pharmacology|October 4, 2008
Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteersPei Hu, Qi Yin, Fabienne Deckert, et al.
The Journal of Clinical Endocrinology and Metabolism|January 15, 2002
Pulsatile insulin secretion by human pancreatic isletsSoon H Song, Lise Kjems, Robert Ritzel, et al.
Diabetes|May 22, 2016
Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor AntagonistMichael A Nauck, Joachim Kind, Lars D Köthe, et al.
Molecular Genetics and Metabolism Reports|September 6, 2023
Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trialReena Sharma, Caroline Hastings, Orna Staretz-Chacham, et al.
The Journal of Clinical Endocrinology and Metabolism|February 11, 2011
Skeletal muscle mitochondrial capacity and insulin resistance in type 2 diabetesSudip Bajpeyi, Magdalena Pasarica, Cedric Moro, et al.
Pageof 2